Cell/Gene Therapy Manufacturing Readiness Urged As A Condition For US Expedited Designation

 
• By Sue Sutter
  
sprinter
Manufacturing readiness is a problem facing the gene and cell therapy industry. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies